These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28315711)

  • 1. Reply to: "Serum HBsAg kinetics in clinical prediction".
    Brunetto M; Cornberg M; Chan HL
    J Hepatol; 2017 Jul; 67(1):193-194. PubMed ID: 28315711
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.
    Thompson A; Locarnini S; Revill P
    Gut; 2017 Aug; 66(8):1534-1535. PubMed ID: 27884921
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D.
    Kao CN; Su TH; Kao JH
    Aliment Pharmacol Ther; 2017 Feb; 45(3):480-481. PubMed ID: 28043091
    [No Abstract]   [Full Text] [Related]  

  • 4. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.
    Moucari R; Martinot-Peignoux M; Mackiewicz V; Boyer N; Ripault MP; Castelnau C; Leclere L; Dauvergne A; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Antivir Ther; 2009; 14(8):1183-8. PubMed ID: 20032548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J; Wang Z; Zhou B; Wang Y; Hou J
    Antivir Ther; 2012; 17(1):71-9. PubMed ID: 22267471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
    Papatheodoridis G; Triantos C; Hadziyannis E; Zisimopoulos K; Georgiou A; Voulgaris T; Vlachogiannakos I; Nikolopoulou V; Manolakopoulos S
    J Viral Hepat; 2015 Dec; 22(12):1079-87. PubMed ID: 26146764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to interferon α-1b in HBeAg-positive chronic hepatitis B: a clue from HBsAg levels.
    Ma Q; Qin B; Gong X; Lu X
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):820-4. PubMed ID: 23411867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
    J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy.
    Wang ML; Chen EQ; Tao CM; Zhou TY; Liao J; Zhang DM; Wang J; Tang H
    Scand J Gastroenterol; 2017 Dec; 52(12):1420-1426. PubMed ID: 28880694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
    Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
    J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum HBsAg kinetics in clinical prediction.
    Jeng WJ; Liaw YF
    J Hepatol; 2017 Jul; 67(1):192-193. PubMed ID: 28315712
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply.
    Niro GA; Smedile A; Andriulli A; Rizzetto M
    Aliment Pharmacol Ther; 2017 Feb; 45(3):481-482. PubMed ID: 28043094
    [No Abstract]   [Full Text] [Related]  

  • 15. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
    Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
    J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
    Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
    Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
    Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
    J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.